Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy.
Animals
Cell Line, Tumor
Cell Survival
/ drug effects
Chemical Phenomena
Colonic Neoplasms
/ drug therapy
Disease Models, Animal
Drug Carriers
/ chemistry
Drug Delivery Systems
Drug Liberation
Fluorouracil
/ administration & dosage
Hemolysis
/ drug effects
Humans
Magnetic Resonance Spectroscopy
Mice
Molecular Structure
Nanoparticles
/ chemistry
Particle Size
Prodrugs
/ chemical synthesis
Spectroscopy, Fourier Transform Infrared
Stearic Acids
/ chemistry
Xenograft Model Antitumor Assays
Xylans
/ chemistry
Cell cytotoxicity
Self-assembled nanoparticles
Xylan
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
received:
16
11
2018
revised:
17
01
2019
accepted:
20
01
2019
pubmed:
27
1
2019
medline:
25
6
2019
entrez:
27
1
2019
Statut:
ppublish
Résumé
In this study, self-assembled nanoparticles based on amphiphilic xylan-stearic acid (Xyl-SA) conjugates have been developed for the efficient delivery of 5-fluorouracil (5-FU) in cancer therapy. The self-assembled behavior of Xyl-SA conjugates in aqueous medium was investigated using pyrene as fluorescent probe. To enhance the loading efficacy of 5-FU, the lipophilic 5-fluorouracil-stearic acid (5-FUSA) prodrug was synthesized and subsequently encapsulated into the hydrophobic core of Xyl-SA NPs. The obtained Xyl-SA/5-FUSA NPs had an appropriate size (~278 nm), high drug loading of 5-FUSA (~14.6 wt%) and high physiological stability. The interaction of the Xyl-SA/5-FUSA NPs with blood components was investigated by hemolysis study. The cell cytotoxic studies demonstrated that Xyl-SA/5-FUSA NPs induced higher cytotoxicity than free drugs against the Human colorectal cancer cells (HT-29, HCT-15). These results indicate that Xyl-SA/5-FUSA NPs can serve as a promising drug delivery system for the efficient delivery of 5-FU in cancer therapy.
Identifiants
pubmed: 30684574
pii: S0141-8130(18)36281-0
doi: 10.1016/j.ijbiomac.2019.01.101
pii:
doi:
Substances chimiques
Drug Carriers
0
Prodrugs
0
Stearic Acids
0
Xylans
0
stearic acid
4ELV7Z65AP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
204-213Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.